| Literature DB >> 26568208 |
Adrien Saliou1,2, François-Clément Bidard1,3, Olivier Lantz1,4, Marc-Henri Stern1,5, Anne Vincent-Salomon1,6, Charlotte Proudhon1,2, Jean-Yves Pierga1,3,7.
Abstract
Triple-negative breast cancer (TNBC) is a highly aggressive disease characterized by a high number of relapses and poor overall survival. The heterogeneity of the disease and the limited treatment options compared to other breast cancer subtypes mainly explain these clinical outcomes. New biomarkers are urgently needed to improve the management of TNBC. Circulating tumor DNA, identified by tumor-related molecular alterations, could be used in the context of non-invasive "liquid biopsy" and help in TNBC diagnosis and treatment decisions. In this review, we discuss the key issues related to the potential of circulating tumor DNA to improve the management of this disease and the future steps to overcome before its implementation into clinical routine within the next 5 years.Entities:
Keywords: circulating tumor DNA; diagnosis; liquid biopsy; therapy; triple-negative breast cancer
Mesh：
Substances：
Year: 2015 PMID： 26568208 DOI： 10.1586/14737159.2016.1121100
Source DB: PubMed Journal: Expert Rev Mol Diagn ISSN： 1473-7159 Impact factor: 5.225